These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 32081465)
1. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Verberk IMW; Hendriksen HMA; van Harten AC; Wesselman LMP; Verfaillie SCJ; van den Bosch KA; Slot RER; Prins ND; Scheltens P; Teunissen CE; Van der Flier WM Neurobiol Aging; 2020 May; 89():99-107. PubMed ID: 32081465 [TBL] [Abstract][Full Text] [Related]
2. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study. Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F; Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834 [TBL] [Abstract][Full Text] [Related]
4. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358 [TBL] [Abstract][Full Text] [Related]
5. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
6. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Verberk IMW; Slot RE; Verfaillie SCJ; Heijst H; Prins ND; van Berckel BNM; Scheltens P; Teunissen CE; van der Flier WM Ann Neurol; 2018 Nov; 84(5):648-658. PubMed ID: 30196548 [TBL] [Abstract][Full Text] [Related]
7. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms. Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812 [TBL] [Abstract][Full Text] [Related]
10. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249 [TBL] [Abstract][Full Text] [Related]
12. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
13. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048 [TBL] [Abstract][Full Text] [Related]
14. Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment. Chen TB; Lee YJ; Lin SY; Chen JP; Hu CJ; Wang PN; Cheng IH Sci Rep; 2019 Sep; 9(1):13984. PubMed ID: 31562355 [TBL] [Abstract][Full Text] [Related]
15. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300 [TBL] [Abstract][Full Text] [Related]
16. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824 [TBL] [Abstract][Full Text] [Related]
17. Preclinical AD predicts decline in memory and executive functions in subjective complaints. van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134 [TBL] [Abstract][Full Text] [Related]